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Retinoic acid (RA)-resistance in breast cancer cells has
been associated with irreversible loss of retinoic acid
receptor b, RARb, gene expression. Search of the causes
aecting RARb gene activity has been oriented at
identifying possible dierences either at the level of one
of the RARb promoters, RARb2, or at regulatory
factors. We hypothesized that loss of RARb2 activity
occurs as a result of multiple factors, including epigenetic
modifications, which can pattern RARb2 chromatin
state. Using methylation-specific PCR, we found
hypermethylation at RARb2 in a significant proportion
of both breast cancer cell lines and primary breast
tumors. Treatment of cells with a methylated RARb2
promoter, by means of the DNA methyltransferase
inhibitor 5-Aza-2’-deoxycytidine (5-Aza-CdR), led to
demethylation within RARb2 and expression of RARb
indicating that DNA methylation is at least one factor,
contributing to RARb inactivity. However, identically
methylated promoters can dierentially respond to RA,
suggesting that RARb2 activity may be associated to
dierent repressive chromatin states. This supposition is
supported by the finding that the more stable repressive
RARb2 state in the RA-resistant MDA-MB-231 cell line
can be alleviated by the HDAC inhibitor, trichostatin A
(TSA), with restoration of RA-induced RARb transcrip-
tion. Thus, chromatin-remodeling drugs might provide a
strategy to restore RARb activity, and help to overcome
the hurdle of RA-resistance in breast cancer. Oncogene
(2000) 19, 1556 – 1563.
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Introduction
Retinoic acid (RA) controls fundamental developmental
processes, induces terminal dierentiation of myeloid
progenitors and suppresses cancer and cell growth
(Smith et al., 1992; Gudas et al., 1994). RA activity is
mediated by nuclear receptors, the retinoic acid
receptors, RARs, that act as RA-dependent transcrip-
tional activators in their heterodimeric forms with
retinoid X receptors, RXRs (Chambon, 1996). RARs
induce local chromatin changes at level of target genes,
containing responsive RA elements (RAREs) by recruit-
ing multiprotein complexes with histone acetyltransfer-
ase (HAT) activity and histone deacetylase (HDAC)
activity, that dynamically pattern chromatin modifica-
tion and regulate gene expression (see for review
Chambon, 1996; Minucci and Pelicci, 1999).
RARs and RXRs, when disrupted, result in severe
developmental defects and neoplastic transformation
(Smith et al., 1992; Gudas et al., 1994; Chambon, 1996).
In breast cancer cells, the expression of one member of
the RARs family, RARb is found consistently down-
regulated or lost (Roman et al., 1992; Shao et al., 1994;
Swisshelm et al., 1994; Li et al., 1995; Widshwendtner et
al., 1997; Xu et al., 1997; Liu et al., 1997). RARb
downregulation can be reversed by RA in estrogen
receptor (ER)-positive, but not in ER-negative breast
carcinoma cell lines, believed to represent more advanced
forms of tumors (Liu et al., 1997). Loss of RA-induced
RARb expression is considered a crucial step in the
development of RA-resistance in breast carcinogenesis.
A complex regulatory region, with two promoters
regulates RARb gene expression. Only one promoter,
RARb2, containing several RA-response elements,
including a canonical and an auxiliary RA response
element, bRARE (de The’ et al., 1990; Valcarel et al.,
1994) is active in human mammary epithelial cells
(HMEC). The transcription of the RARb2 promoter is
mediated bymultiple RARs including, RARa andRARb
itself (Chiba et al., 1997) able to recruit coactivator and
corepressor protein complexes with HAT/HDAC activ-
ities, respectively (Chambon, 1996). To understand why
RARb activity is downregulated, or lost, in breast cancer,
intense search has been oriented at identifying possible
alterations aecting either the RARb2 promoter, or
regulatory factors (Seewaldt et al., 1995; Widschwendt-
ner et al., 1997; Xu et al., 1997; Tsou et al., 1998; Folkers
et al., 1998).
DNA methylation is an epigenetic change that
induces chromatin modifications and repression of
transcription via a methyl CpG binding protein
MeCP2, and recruitment of a Sin3A/HDAC corepres-
sor complex (Nan et al., 1998; Wade et al., 1998;
Razin, 1998; Ng and Bird, 1999; Jones and Wole,
1999). For this reason, we decided to investigate
whether RARb2 promoter was aected by DNA
methylation. Indeed, we found hypermethylation at
the RARb2 promoter both in breast carcinoma cell
lines, and a significant proportion of primary breast
tumors. Treatment with the methyltransferase inhibitor
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5-Aza-CdR partially reversed the DNA methylation
state, and restored RARb transcription, thus indicating
that DNA methylation is at least one factor contribut-
ing to RARb inactivity. However, the available data
indicate that DNA methylation is only a component of
the observed RARb gene inactivity. Very likely, RA-
inducibility of RARb gene is influenced by modifica-
tions altering RARb2 chromatin, produced by the
nuclear receptors that act at bRARE (RARa and the
same RARb), as well as DNA methylation.
Results
The RARb2 promoter is methylated in breast cancer cell
lines independently of their ER status and RA-inducibility
RARb transcription was first tested in a panel of breast
cancer cell lines grown in the absence of exogenous
RA, by reverse transcriptase-PCR (RT–PCR), using
primers encompassing exons 5 and 6 (de The’ et al.,
1990; van der Leede et al., 1992; Toulouse et al., 1997).
Under these conditions, only one cell line, Hs578t,
produced a detectable 256 bp RT –PCR product
(Figure 4a). Thus, we confirmed previous reports that
RARb gene expression is down regulated/lost in breast
cancer cell lines. Growing cells in the presence of RA
can assess the distinction between downregulation and
loss. As previously reported (Swisshelm et al., 1994;
Liu et al., 1997; Shang et al., 1999), we observed
induction of RARb expression and growth inhibition in
T47D, MDA-MB-435, MCF7 and ZR75-1 cell lines
treated for 48 h with 1 mM RA, but not in the MDA-
MB-231 and MDA-MB-468 cell lines.
To see whether the RARb2 methylation status
correlated with the ER status, we examined the methyla-
tion status at RARb2 in a panel of ER-positive (MCF7,
T47D, ZR75-1) and ER-negative (Hs578t, MDA-MB-
231, MDA-MB-435, MDA-MB-468) cell lines.
By Southern blotting we analysed the CpG island of
the RARb2 promoter within a 7.5 kb XbaI DNA
fragment encompassing the TATA box, the bRARE,
the transcriptional start site (TS) and the 5’ untranslated
region of exon 5 (Figure 1a). In this region we can
identify nine HpaII sites (Shen et al., 1991; Baust et al.,
1996). The DNA methylation status was analysed by
using the methylation-sensitive enzyme, HpaII (Figure
1b). MspI, the isoschizomer of HpaII, insensitive to
methylation, was used as a positive control. The PCR
probe spans the bRARE and the TATA box regions
(Figure 1a). The same 7.5 kb region was previously
analysed in a colon carcinoma cell line, and the size of all
the possible fragments relative to the most 3’HpaII site
were reported (Cote’ and Momparler, 1997). A repre-
sentative blot is shown in Figure 1b. Genomic DNA
from the ER-positive, RA-inducible cell line T47D is
digested to completion, indicating that it is not
methylated at any of the HpaII sites. In contrast, DNA
from the ER-positive, RA-inducible ZR75-1 cell line and
DNA from the ER-negative, RA-resistant MDA-MB-
231 cell line showed to be dierentially methylated at the
methylation-sensitive sites. (Figure 1b). Using methyla-
tion-specific PCR (MSP), we further analysed a 616 bp
long RARb2 region from nucleotide 481 to nucleotide
1096 (Shen et al., 1991) in all the cell lines. MSP entails
the modification of genomic DNA by sodium bisulfite
that converts all unmethylated, but not methylated,
cytosine to uracil (Herman et al., 1996). The distribution
of CpGs expected after Na bisulfite modification and the
four MSP primers (1 – 4) is reported in Figure 2a. The
genomic DNAs from four breast cancer cell lines ZR751,
MCF7, MDA-MB-231, MDA-MB-468 showed partial
to complete methylation of the promoter region (Figure
2b). The human mammary epithelial cell (HMEC) strain
48R, expressing RARb and three breast cancer cell lines,
the RARb-positive Hs578t and the RA-inducible MDA-
MB-435 and T47D, revealed only the (U) unmethylated
PCR products (Figure 2b).
These results indicate that hypermethylation of the
RARb2 promoter occurs in breast cancer cell lines
irrespective of the ER status, and can be detected in
both RA-inducible, and RA-resistant breast cancer
cells.
RARb2 is unmethylated in both mortal and immortalized
HMEC, but is methylated in primary breast tumors
Next, we asked whether hypermethylation of RARb2
promoter in cell lines has correlates in clinical breast
cancer. As a normal control we analysed the HMEC
mortal strains (48R, 172R), that are the closest
representation of normal mammary epithelial cells
available. We also analysed two immortal mammary
epithelial strains (184A1 and 184B5). The DNA of
these strains was found to be unmethylated (Figure 2c).
Consequently, methylation of RARb2 may be an event
in the progression of breast cancer, following im-
mortalization. Genomic DNAs from three paranated
samples of breast tumors, two ER-positive (T1, T2)
and one ER-negative (T3), estimated to contain more
than 90% tumor cells, were analysed with all MSP
primer pairs, and shown to be partially methylated
(Figure 2d). Both microdissected breast stroma, and
microdissected normal epithelial cells were found
unmethylated at RARb2 (our unpublished observa-
tions), making it very likely that the U products in the
tumor samples were amplified either from residual
normal epithelial cells, or stromal cells mixed to tumor
cells. DNAs from matching histologically tumor free
lymph node samples (N1 –N3), were similarly analysed
and produced only the unmethylated PCR products
(Figure 2d). The DNA of additional 21 tumors was
performed using two sets of primer pairs (U3/M3 and
U4/M4). Fifteen (7 ER-positive and 8 ER-negative) of
the 24 tumors presented methylation at the RARb2
promoter. With the same primer sets hypermethylation
at RARb2 was detected in the DNA of ten out of 39
primary breast tumors collected, and analysed inde-
pendently, at the Johns Hopkins University.
The overall data indicate that hypermethylation at
RARb2 promoter occurs in approximately one third of
primary breast tumors, and that the RARb2 methyla-
tion state is independent of the ER status of the tumor.
5-Aza-CdR induces partial demethylation at the RARb2
CpG island and reactivation of RARb gene expression
In order to determine whether DNA methylation is
aecting, at least in part, RARb gene expression, we
treated all the cell lines showing methylation at the
RARb2 promoter with the DNA methyltransferase
inhibitor, 5-Aza-CdR. Treatment of cells with either
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0.4 or 0.8 mM 5-Aza-CdR for 3 days, led to partial
demethylation of the CpG rich RARb2 region. This was
evident both by Southern analysis in the MDA-MB-231
cell line (Figure 1b, left panel), and by MSP in all cell
lines (Figure 3). Moreover, 5-Aza-CdR treatment
resulted in reactivation of gene expression both in RA-
inducible MCF7 and ZR75-1, and RA-resistant MDA-
MB-231 and MDA-MB-468 cells (Figure 4b). We asked
whether reactivation of RARb expression by 5-Aza-CdR
A-resistant cells could be enhanced by RA. By using non-
quantitative RT –PCR, we could not appreciate a
dierence in the level of RARb transcription in MDA-
MB-231 cells treated with 0.4 mM 5-Aza-CdR alone, or in
combination, with 1 mM RA (Figure 4c). In this
experiment, 5-Aza-CdR alone, or in combination with
RA, produced 63 and 96% growth inhibition respec-
tively. In the same experiment, treatment with 1 mM RA
alone produced a negligible eect on growth inhibition
(52%). A synergistic eect of the two drugs on cancer
cells was previously reported (Cote’ and Momparler,
1997; Bovenzi et al., 1999).
These data indicate that DNA methylation is, at least,
one factor influencing the downregulation/loss of RARb
transcription in breast cancer cell lines with a methylated
RARb2 promoter. Cells treated with 5-Aza-CdR alone,
or in combination with RA, showed re-expression of
RARb, which may have contributed, along with the toxic
5-Aza-CdR, to the observed growth inhibition.
The HDAC inhibitor TSA can reactivate RARb
expression in RA-resistant cells; demethylation of the
RARb2 promoter is not an absolute requirement for
RARb reactivation
The chromatin status at a given locus can be
dynamically influenced by the degree of acetylation/
Figure 1 Methylation sensitive Southern blotting of the RARb2 promoter. (a) Genomic map of the RARb2 promoter-exon 5
region indicating the position of HpaII sites (H) relative to bRARE, TATA, transcription start site (TS) and the ATG. (b) Southern
analysis of : T47D and ZR571 DNAs digested with XbaI, HpaII (right) and MspI and MDA-MB-231 cells before, and after
treatment with 0.8 mM 5-Aza-CdR for 3 days (left)
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deacetylation due to HAT/HDAC activities. Absence
of RARb regulatory factors, like RARa, as well as
DNA-methylation, can contribute to pattern chromatin
modifications at RARb promoter in RA-resistant cell
lines. One of these cell lines, MDA-MB-231, lacks RA-
inducible RARa activity (Shao et al., 1994) and
displays a RARb2 methylated promoter. We decided
to probe indirectly whether the level of HDAC at
RARb2 can influence RARb expression, by testing the
eect of TSA, a HDAC inhibitor on MDA-MB-231
cells (Yoshida et al., 1995). Cells were treated for 2
days, in the presence or absence of 100 ng/ml TSA
alone, or in combination, with 1 mM RA. By using
RT –PCR, it was clear that, unlike cells treated with
RA alone, cells treated with a combination of RA and
TSA re-expressed RARb mRNA (Figure 4d). Under
the same experimental conditions, 100 ng/ml TSA
alone, or in combination with 1 mM RA, produced 77
Figure 2 MSP analysis of DNA from cell lines and primary tumors. (a) Distribution of the methylated CpGs (filled circles) in the
RARb2 promoter region spanning nt 498 to nt 1096 and position of the MSP primers. (b) MSP analysis of a panel of breast
carcinoma cell lines. U and M products amplified with the four sets of MSP primers in ER-positive and -negative cell lines and the
mortal HMEC (48R) strain. (c) MSP analysis of two mortal (48R and 172R) and two immortal (184A1 and 184B5) HMEC strains.
(d) MSP analysis of three breast tumors (T1 –T3) and matching tumor cell free lymph nodes (N1 –N3)
Figure 3 Treatment with 5-Aza-CdR induce partial de-methyla-
tion. MSP analysis of DNA of four breast cancer cell lines before
and after treatment for 3 days with 0.8 mM 5-Aza-CdR
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and 92% growth inhibition, respectively. Treatment
with 1 mM RA alone did not aect significantly growth
inhibition (52%). By MSP analysis, we could assess
that RARb expression was restored in the presence of a
methylated RARb2 promoter. The MSP profile
obtained with primer set 3, spanning the bRARE
region is reported in Figure 5. This finding indirectly
shows that global alterations of HDAC activity,
generated by TSA in MDA-MB-231 cells, involved
RARb2 resulting in RA-induced RARb expression.
Further, demethylation at RARb2 did not seem to be
an absolute requirement for RARb gene expression in
MDA-MB-231 cells. Noteworthy, persistence of methy-
lation at RARb2 was observed also in MCF7 cells
where RARb transcription could be restored in the
presence of RA (data not shown). Growth inhibition
was observed in cells treated with TSA alone, or in
combination, with RA. Very likely, RARb along with
TSA, a drug known to induce growth inhibition
(Yoshida et al., 1995), contributed to the massive
growth inhibitory eect that we observed.
Discussion
RARb2 promoter is methylated in breast cancer
In this study, we show evidence that, in breast cancer
cells, RARb2 promoter undergoes DNA hypermethyla-
tion, an epigenetic change known to induce chromatin
modifications and influence gene expression (Razin,
1998; Ng and Bird, 1999; Jones and Wole, 1999). We
detected methylation of the RARb2 promoter region,
both in breast carcinoma cell lines, and a significant
proportion of primary breast tumors. RARb2 methyla-
tion status did not correlate with the ER status of
breast cancer cells and was observed both in in situ
lesions and invasive tumors (our unpublished observa-
tions).
It is not clear when epigenetic changes occur during
breast cancer progression. However, methylation of the
promoter was not detected in both mortal, and
Figure 4 Treatment with 5-Aza-CdR and TSA triggers re-expression of RARb. (a) RT–PCR of mortal HMEC strains 48R and
172R and breast cancer cell lines. Brain RNA was used as a control. (b) RT–PCR of breast cancer cell lines treated for 3 days with
0.4 mM (lanes 2, 5, 8 and 11) and 0.8 mM (lanes 3, 6, 9 and 12) 5-Aza-CdR and untreated cells (lanes 1, 4, 7 and 10). (c) RT–PCR of
MDA-MB-231 cells untreated (lane 2) in comparison with cells treated for 3 days with 1 mM RA (lane 3), 0.4 mM 5-Aza-CdR (lane
4), 0.4 mM 5-Aza-CdR+1 mM RA (lane 5). Hs578t used as positive control (lane 6). (d) RT–PCR of MDA-MB-231 cells untreated
(lane 1), in comparison with cells treated for 48 h with 1 mM RA (lane 2), 100 ng/ml TSA (lane 3), 100 ng/ml TSA+1 mM RA (lane
4); solvent (lane 5)
Figure 5 DNA methylation in RARb2 promoter of MDA-MB-
231 cells expressing RA-induced RARb after TSA treatment.
MSP analysis of MDA-MB-231 cells using primers 3 shows that
there is no demethylation of the bRARE containing region in
cells treated with 1 mM RA (lane 3), 100 ng/ml TSA (lane 4),
100 ng/ml TSA+1 mM RA (lane 5); in comparison with untreated
cells (lane 2), or cells grown in the presence of solvent (lane 6).
MSP of Hs578t was used as a control (lane 1)
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immortal human mammary epithelial cell (HMEC)
strains, as well as in normal microdissected breast
epithelial cells (our unpublished observations). These
results suggest that aberrant methylation of the RARb2
CpG island may be a later event following immorta-
lization. Treatment of breast cancer cells presenting
with a methylated RARb2, with the demethylating
agent 5-Aza-CdR, induced partial DNA demethylation
and restored RARb gene expression. This evidence
clearly indicates that DNA methylation is at least a
component contributing to RARb downregulation/loss.
RARb2 methylation state and RA-inducibility
The correlation between RARb2 methylation and RA-
inducibility in dierent breast cancer cell lines,
indicates that DNA methylation is not the only factor
influencing RARb silencing. Survey of dierent breast
cancer cell lines shows that RARb is downregulated,
but can be reinduced by RA both in MDA-MB-435
and T47D cells, with unmethylated RARb2 promoter
and in MCF7 and ZR751 cells, with a methylated
promoter. In contrast, in MDA-MB-231 and MDA-
MB-468 cell lines the methylated RARb2 promoter is
indierent to RA treatment. Apparently, dierent
degrees of repression can aect RARb2 promoter,
and only in some cases, the ligand is sucient to
alleviate methyl-directed repression. Extinction of RARb
transcription must be determined by a stable repressive
state in the chromatin structure determined by more
than one mechanism, including DNA methylation.
DNA-methylation might be secondary to RARb2
promoter inactivity
We hypothesize that low intracellular levels of RA in
breast cancer cells may induce chromatin structure
alterations at RARb2, similar to the ones observed in
the P19 embryonal carcinoma cell line (Bhattacharyya
et al., 1997). Although the mechanism of chromatin
structure alterations are not fully understood, current
evidence indicates that local histone acetylation is a
crucial factor (Razin, 1998). An altered chromatin
environment may predispose to DNA methylation, a
condition that might further aect histone deacetyla-
tion at RARb2 (Razin, 1998; Ng and Bird, 1999; Jones
and Wole, 1999). The first to propose that gene
inactivity ‘invites’ de novo methylation was Bird (1986).
The hypothesis was further refined, after the discovery
of the mechanistic link between DNA methylation and
chromatin conformation mediated by the MeCP2/
Sin3A/HDAC corepressor complex (Nan et al., 1998;
Wade et al., 1998). According to the revisited
hypothesis, Ng and Bird (1999) propose that: ‘DNA
methyltransferase – either independently or assisted by
accessory proteins – may be capable of reading the
histone acetylation pattern on the chromatin and its de
novo methyltransferase activity can respond dieren-
tially to dierent states of chromatin modification. In
this case, deacetylated chromatin would provoke de
novo methylation. This self-reinforcing mechanism,
supported by DNA methylation and histone deacetyla-
tion, could provide a stable state of inactive chromatin,
unless overcome by other mechanisms’.
RARb2 promoter in breast cancer might provide an
ideal system to test this hypothesis, given the
heterogeneous correlation between its methylation state
and RA-inducibility in dierent breast cancer cells.
Unmethylated, RA-inducible RARb2 promoters are
expected to be associated with, either an active
chromatin state, or a mild repressive state. A
methylated RARb2 promoter is expected to be
associated with a more repressive chromatin environ-
ment. As a consequence, transcription from a
methylated promoter should be possible, either by
recruiting consistent HAT activity, or by inhibiting
excessive HDAC activity. These speculations are so far
supported by compelling circumstantial evidence.
Notably, RA can induce both RARa and RARb in
MCF7 cells from a RARb2 methylated promoter (Shao
et al., 1994; Shang et al., 1999; our unpublished
observations). This suggests that RA may trigger
recruitment of HAT activity at RARb2, sucient to
override methylation-related chromatin constraints. On
the contrary, in the MDA-MB-231 cells we saw that
RA-induced RARb transcription is possible after
treatment with TSA, a HDAC inhibitor, already
known to induce chromatin alterations at RARb2
promoter in P19 cells (Minucci et al., 1997). Analysis
of the DNaseI sensitivity pattern, in and around
RARb2, as well as the assessment of RARb2 histone
acetylation state (Keshet et al., 1986; Hebbes et al.,
1994; Eden et al., 1998), in both MCF7 and MDA-
MB-231 cells will give us an idea of the relation
between chromatin environments and RARb transcrip-
tion. Moreover, these studies are expected to shed light
on the relation of histone acetylation and methylation
of the RARb2 promoter. This issue is of particular
interest since it is not yet completely clear whether
DNA demethylation is indeed always required to
restore transcription from genes with fully methylated
promoters (Cameron et al., 1999; Ferguson et al., 1998;
Razin, 1998; Ng and Bird, 1999).
In conclusion, we provide evidence that DNA-
methylation at RARb2 promoter in breast cancer cells
is aecting, at least in part, RARb transcription. We
argue that DNA-methylation is secondary to the inactive
state at RARb2 promoter and may contribute to create a
stable repressive RARb2 environment and extinction of
RARb transcription. Further understanding of epige-
netic changes and chromatin alteration at RARb2 may
have preventive and therapeutic implications. Changes
altering RARb2 chromatin structure and RARb tran-
scription in breast cancer might be prevented in the
presence of supraphysiological levels of RA (Minna and
Mangeldorf, 1997). Knowledge of RARb2-methylation
state of primary breast cancers might be useful to identify
tumors that are more likely to respond to RA-therapy.
Finally, the possibility to re-induce RARb activity in
RA-resistant breast cancer cells, using both TSA and
RA, a combination proven to be eective for treating
leukemia (Grignani et al., 1998; Guidez et al., 1998; He et
al., 1998; Lin et al., 1998; Warrell et al., 1998), might
have therapeutic implications also in the treatment of
RA-resistant breast tumors.
Materials and methods
Cell cultures
Human epithelial mammary cells (HEMC) from reduction
mammoplasty including three mortal strains, 184, 48R and
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172R, and two immortal strains, 184A1 and 184B5, were
obtained and cultured according to the protocols designed by
Dr Martha Stampfer (see the HMEC Homepage, http://
www.lbl.gov/*mrgs/index.htlm) using Clonetics (Walkers-
ville, MD, USA) reagents.
Human breast cancer cell lines were maintained in
Dulbecco’s modified Eagle’s medium (GIBCO) (Hs578t,
MCF-7, MDA-MB-231 and T47D) or IMEM medium
(Biofluids) (MDA-MB-435, MDA-MB-468, ZR751) with
5% fetal calf serum (FCS). For drug treatments, exponen-
tially growing cells were seeded in 10 cm2 plates at a density
of 36105 cells/plate or in 6-well plates at 16105 cells/well.
Cells were allowed to attach overnight before the addition of
the appropriate concentration of 5-Aza-2’ deoxycytidine (5-
Aza-CdR) (Sigma), Trichostatin A (TSA) (Sigma) or RA
(Sigma). When reduction of retinoids was required, cells were
treated in either medium with 0.5% FCS or charcoal-dextran
stripped FCS (Hyclone). At the indicated time points, both
attached and detached cells were harvested, counted with
Trypan Blue (Life Technologies) and processed for DNA or
RNA extraction. 5-Aza-CdR was dissolved in 0.45% NaCl
containing 10 mM sodium phosphate (pH 6.8). Trichostatin
A and all-trans-retinoic acid (RA) (Sigma) were reconstituted
in absolute ethanol (solvent). The growth inhibition (%) was
calculated as: (1-NT/NC)6100, where NT is the number of
treated cells and NC is the number of control cells.
Tissue samples
Normal and tumor tissues were collected from existing tumor
banks (Instituto per lo Studio e la Cura dei Tumori, Milan;
the Cancer Center, Rotterdam, the Johns Hopkins Breast
Cancer Program, Baltimore, MD, USA). All tumor samples
were obtained from excess clinical specimens and institutional
guidelines for the acquisition and maintenance of such
specimens were followed.
DNA and RNA extraction
Extraction of DNA and RNA from breast cancer cell lines
was performed by using DNAzol and Trizol respectively (Life
Technologies) according to the manufacturer’s instructions.
Genomic DNA was further treated with 500 mg/ml proteinase
K at 558C, extracted with phenol-chloroform-isoamylic
alcohol (24 : 24 : 1) (CIA) and ethanol precipitated. Extraction
of DNA from paranated breast cancer and lymph node
tissues was essentially performed as previously described
(Formantici et al., 1999). One to three consecutive sections
estimated to contain at least 90% tumor cells were incubated
at 588C overnight in 200 ml of extraction buer (50 mM KCl,
10 mM Tris-HCl (pH 7.5), 2.5 mM MgCl2, 0.1 mg/ml gelatin,
0.45% NP-40, 0.45% Tween 20, and the solution was heated
at 958C for 15 min to inactivate the proteinase K and then
centrifuged at 6000 r.p.m. The DNA in the supernatant was
used for analysis.
Southern blotting
Genomic DNA (7 mg) was digested overnight with 15 U/mg of
XbaI, HpaII and MspI enzymes, electrophoresis on a 0.8%
agarose gel and transferred to Hybond-N filter. A 227 bp probe
was amplified using the sense 5’-AGA GTT TGA TGG AGT
TGG GTG GAG-3’ and antisense 5’-CAT TCG GTT TGG
GTC AAT CCA CTG-3’ primers, gel purified and labeled with
32P-dCTP using the Megaprime DNA labeling system (Amer-
sham). After hybridization the filters were washed and exposed
to X-ray film at7808C for autoradiography.
Methylation specific PCR (MSP)
Bisulfite modification of genomic DNA was essentially
performed as described by Herman et al. (1996). Modified
DNA was used immediately or stored in aliquots at 7208C.
The PCR mixture contained 16PCR buer (16.6 mM
ammonium sulfate, 67 mM Tris (pH 8.7), 1.5 mM MgCl2),
dNTPs (each at 1.25 mM), primers (300 ng each per reaction),
and bisulfite-modified DNA (50 ng) or unmodified DNA
(50 ng). Reactions were hot started at 958C before the
addition of 2.5 U of Taq polymerase (Qiagen). Amplification
was carried out in a Thermal Cycler 480 Perkin Elmer for 30
cycles (1 min at 948C, 1 min at the annealing temperature (at)
selected for each primer pair, 1 min at 728C), followed by
4 min at 728C. Twelve ml of the PCR reaction were
electrophoresed onto 1.5% agarose gels, stained with
ethidium bromide and visualized under UV. Two primer
pairs, W3 sense 5’-CAGCCCGGGTAGGGTTCACC-3’, W3
antisense 5’-CCGGATCCTACCCCGACGG-3’, and W4
sense 5’-CCGAGAACGCGAGCGATCC-3’ and W4 anti-
sense 5’-GGCCAATCCAGCCGGGGCG-3’, were designed
on the human RARb2 sequence (Shen et al., 1991) and used
to control the Na bisulfite modification. The primer pairs
selected to detect the unmethylated DNA were as follows: U1
sense 5’-GTG GGT GTA GGT GGA ATA TT-3’ and U1
antisense 5’-AAC AAA CAC ACA AAC CAA CA-3’ (at
558C); U2 sense 5’-TGT GAG TTA GGA GTA GTG TTT
T-3’ and U2 antisense 5’-TTC AAT AAA CCC TAC CCA-3’
(at 498C); U3 sense 5’-TTA GTA GTT TGG GTA GGG
TTT ATT-3’ and U3 antisense 5’-CCA AAT CCT ACC CCA
ACA-3’ (at 558C); U4 sense 5’-GAT GTT GAG AAT GTG
AGT GAT TT-3’ and U4 antisense 5’-AAC CAA TCC AAC
CAA AAC A-3’ (at 558C); The sequences of the primers to
detect the methylated DNA were: M1 sense 5’-AGC GGG
CGT AGG CGG AAT ATC-3’ and M1 antisense 5’-CAA
CGA ACG CAC AAA CCG ACG-3’ (at 638C); M2 sense 5’-
CGT GAG TTA GGA GTA GCG TTT C-3’ and M2
antisense 5’-CTT TCG ATA AAC CCT ACC CG-3’ (at
578C); M3 sense 5’-GGT TAG TAG TTC GGG TAG GGT
TTA TC-3’ and M3 antisense 5’-CCG AAT CCT ACC CCG
ACG-3’ (at 648C); M4 sense 5’-GTC GAG AAC GCG AGC
GAT TC-3’ and M4 antisense 5’-CGA CCA ATC CAA CCG
AAA CG-3’ (at 648C).
The distrubution of the CpG methylated sites and the
position of the primers is reported in Figure 2. M and U
primers were designed in the same regions, with one or two
nucleotide dierences to meet annealing requirements.
Fragment M3 (position 773 – 1007) contains the bRARE
(792 – 808) and the transcription start site (position 844);
fragment M4 (position 949 – 1096) contains an Sp1 element
(position 1074 – 1081).
RT–PCR
The exon 5 (sense primer 5’-GAC TGT ATG GAT GTT
CTG TCA G-3’) and exon 6 (antisense primer 5’-ATT TGT
CCT GGC AGA CGA AGC A-3’) were designed on the
basis of published RARb2 transcript (de The’ et al., 1990;
van der Leede et al., 1992) and used to amplify 50 ng of
DNase treated total RNA using the Superscript One-Step
RT–PCR System (Life Technologies). RT–PCR with actin
primers (sense primer 5’-ACC ATG GAT GAT GAT ATC
G-3’ and antisense primer 5’-ACA TGG CTG GGG TGT
TGA AG-3’ was used as an internal RNA control.
Acknowledgments
We thank Drs WEC Bradley (Montreal) and X-Q Zhang
(La Jolla) for initial helpful discussions on the idea behind
this work and reagents and Dr A Hoogeveen for critical
suggestions; Dr M Stampfer for the gift of the HMEC
strains; Dr A de Klein for providing DNA from breast
tumors. Funding for this work were provided by Associa-
zione Italiana Ricerca sul Cancro (AIRC) and by
BC980803 (USA) to N Sacchi.
Epigenetic modifications in the RARb2 promoter of breast cancer cells
SM Sirchia et al
1562
Oncogene
References
Baust C, Redpath L and Schwarz E. (1996). Int. J. Cancer,
67, 409 – 416.
Bhattacharyya N, Dey A, Minucci S, Zimmer A, John S,
Hager G and Ozato K. (1997). Mol. Cell Biol., 17, 6481 –
6490.
Bird A. (1986). Nature, 321, 209 – 213.
Bovenzi V, Le NLO, Cote’ S, Sinnet D, Momparler LF and
Momparler RI. (1999). Anticancer Drugs, 10, 471 – 476.
Cameron EE, Bachman KE, Myohanen S, Herman JG and
Baylin SB. (1999). Nature Genet., 21, 103 – 107.
Chambon P. (1996). FASEB J., 10, 940 – 954.
Chiba H, Cliord J, Metzger D and Chambon P. (1997).
Mol. Cell Biol., 17, 3013 – 3020.
Cote’ S and Momparler RL. (1997). Anticancer Drugs, 8,
56 – 61.
De The’ H, del Mar Vivanco-Ruiz M, Tiollais P, Stunnen-
berg HG and Dejan A. (1990). Nature, 343, 177 – 180.
Eden S, Hashimshony T, Keshet I, Cedar H and Torne AW.
(1998). Nature, 394, 842.
Ferguson AT, Lapidus RG and Davidson NE. (1998).
Oncogene, 17, 577 – 583.
Folkers GE, van der Burg B and van der Saag PT. (1998). J.
Biol. Chem., 273, 32200 – 32212.
Formantici C, Orlandi R, Ronchini C, Pilotti S, Ranzani
GN, Colnaghi MI and Menard S. (1999). J. Pathol., 187,
424 – 427.
Grignani F, Dematteis S, Nervi C, Tomassoni L, Gelmetti V,
Cioce M, Fanelli M, Ruthardt M, et al. (1998). Nature,
391, 815 – 818.
Gudas LJ, Sporn MB and Roberts AB. (1994). In: The
Retinoids. Biology, Chemistry and Medicine. Raven Press:
New York, pp. 443 – 520.
Guidez F, Ivins S, Zhu J, Soderstrom M, Waxman S and
Zelent A. (1998). Blood, 91, 2634 – 2637.
He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent
A and Pandolfi PP. (1998). Nature Genet., 18, 126 – 135.
Hebbes TR, Clayton AL, Thorne AW and Crane-Robinson
C. (1994). EMBO J., 13, 1823 – 1830.
Herman JG, Gra JR, Myohanen S, Nelkin BD and Baylin
SB. (1996). Proc. Natl. Acad. Sci. USA, 93, 9821 – 9826.
Jones PL and Wole AP. (1999). Semin. Cancer Biol., 9,
339 – 347.
Keshet I, Lieman-Hurwitz J and Cedar H. (1986). Cell, 44,
535 – 543.
Li X-S, Shao Z-M, Sheikh MS, Eiseman JL, Sentz D, Jetten
AM, Chen J-C, Dawson ML, Aisner S, Rishi AK,
Gutierrez P, Schnapper L and Fontana JA. (1995). J. Cell
Physiol., 165, 449 – 458.
Lin RJ, Nagy I, Inoue S, Shao W, Miller Jr WH and Evans
RM. (1998). Nature, 391, 811 – 814.
Liu Y, Lee M-O, Wang H-G, Li Y, Hashimoto Y, Klaus M,
Reed JC and Zhang X-K. (1997). Mol. Cell Biol., 16,
1138 – 1149.
Minucci S, Horn V, Bhattacharyya N, Russanova V,
Ogryzko VV, Gabriele L, Howard BH and Ozato K.
(1997). Proc. Natl. Acad. Sci. USA, 94, 11295 – 11300.
Minna JD and Mangeldorf DJ. (1997). J. Natl. Cancer Inst.,
89, 602 – 604.
Minucci S and Pelicci P. (1999). Semin. Cell Dev. Biol., 2,
215 – 225.
Ng H-H and Bird A. (1999). Curr. Opin. Genet. Dev., 9, 158 –
163.
Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM,
Eisenman RN and Bird A. (1998). Nature, 393, 386 – 389.
Razin A. (1998). EMBO J., 17, 4905 – 4908.
Roman SD, Clarke CL, Hall RE, Alexander IE and
Sutherland RL. (1992). Cancer Res., 52, 2236 – 2242.
Seewaldt VI, Johnson BS, Parker MB, Collins SJ and
Swisshelm K. (1995). Cell Growth Dier., 6, 1077 – 1088.
Shao Z-M, Sheikh MS, Chen JC, Kute T, Aisner S, Schnaper
L and Fontana JA. (1994). Int. J. Oncol., 4, 849 – 853.
Shang Y, Baumrucker CR and Green MH. (1999). J. Biol.
Chem., 274, 18005 – 18010.
Shen S, Kruyt FA, den Hertog J, van der Saag FT and
Kruijer W. (1991). DNA Seq., 2, 111 – 119.
Smith MA, Parkinson Dr, Cheson BD and Friedman MA.
(1992). J. Clin. Oncol., 10, 839 – 864.
Swisshelm K, Ryan K, Lee X, Tsou HC, Peacoque M and
Sager R. (1994). Cell Growth Dier., 5, 133 – 141.
Toulouse A, Morin J, Pelletier M and Bradley WEC.(1997).
BBA, 1309, 1 – 4.
Tsou HC, Yao YJ, Xie XX, Ping XL and Peacocke M.
(1998). Exp. Cell Res., 245, 221 – 227.
Valcarel R, Holz H, Garcia Jimenez C, Barettino D and
Stunnenberg HG. (1994). Genes Dev., 8, 3068 – 3079.
Van der Leede BJ, Folkers GE, Kruyt FA and van der Saag
PT. (1992). Biochem. Biophys. Res. Commun., 188, 695 –
702.
Wade PA, Jones PL, Vermaak D, Veenstra GJ, Imhof A,
Sera T, Tse C, Ge H, Shi YB, Hansen JC and Wolfee AP.
(1998). Cold Spring Harb. Symp. Quant. Biol., 63, 435 –
445.
Warrell Jr, RP, He LZ, Richon V, Callega E and Pandolfi PP.
(1998). J. Natl. Cancer Inst., 90, 1621 – 1625.
Widschwendtner M, Berger J, Daxenbichler G, Muller-
Holzner E, Widschwendtner A, Mayr A, Marth C and
Zeimet AG. (1997). Cancer Res., 17, 4158 – 4161.
Xu XC, Sneige N, Liu X, Nandagiri R, Lee JJ, Lukumanji F,
Hortobagy G, Lippman SM, Dhingra K and Lotan R.
(1997). Cancer Res., 57, 4992 – 4996.
Yoshida M, Horinouchi S and Beppu T. (1995). Bioessays,
17, 423 – 430.
Oncogene
Epigenetic modifications in the RARb2 promoter of breast cancer cells
SM Sirchia et al
1563
